Login to Your Account


Regeneron climbs as Eylea becomes the little engine that could

By Marie Powers
Staff Writer

Wednesday, August 6, 2014
Regeneron Pharmaceuticals Inc. had more good news to crow about Tuesday, reporting that second quarter global net sales of Eylea (aflibercept) increased 53 percent, to $662 million, over the same period a year earlier, including sales of $415 million in the U.S. – a 26 percent jump based on a modest decrease in distributor inventory in the second quarter of 2013 – and $247 million in the rest of world.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription